留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

自身免疫性疾病患者使用复方磺胺甲噁唑预防卡氏肺孢子菌病研究进展

阙咏图 李鹏冲 张奉春

阙咏图, 李鹏冲, 张奉春. 自身免疫性疾病患者使用复方磺胺甲噁唑预防卡氏肺孢子菌病研究进展[J]. 协和医学杂志, 2023, 14(1): 196-202. doi: 10.12290/xhyxzz.2022-0131
引用本文: 阙咏图, 李鹏冲, 张奉春. 自身免疫性疾病患者使用复方磺胺甲噁唑预防卡氏肺孢子菌病研究进展[J]. 协和医学杂志, 2023, 14(1): 196-202. doi: 10.12290/xhyxzz.2022-0131
QUE Yongtu, LI Pengchong, ZHANG Fengchun. Analysis on Prophylaxis of Pneumocystis Carini Pneumonia by Trimethoprim-Sulfamethoxazole in Patients with Autoimmune Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 196-202. doi: 10.12290/xhyxzz.2022-0131
Citation: QUE Yongtu, LI Pengchong, ZHANG Fengchun. Analysis on Prophylaxis of Pneumocystis Carini Pneumonia by Trimethoprim-Sulfamethoxazole in Patients with Autoimmune Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 196-202. doi: 10.12290/xhyxzz.2022-0131

自身免疫性疾病患者使用复方磺胺甲噁唑预防卡氏肺孢子菌病研究进展

doi: 10.12290/xhyxzz.2022-0131
详细信息
    通讯作者:

    张奉春, E-mail: zhangfccra@aliyun.com

  • 中图分类号: R593.2

Analysis on Prophylaxis of Pneumocystis Carini Pneumonia by Trimethoprim-Sulfamethoxazole in Patients with Autoimmune Diseases

More Information
  • 摘要: 随着糖皮质激素、免疫抑制剂、小分子靶向药物及生物制剂的应用,自身免疫性疾病患者由于卡氏肺孢子菌机会性感染发生卡氏肺孢子菌病(pneumocystis carini pneumonia,PCP)的风险明显增加,且此类PCP较艾滋病相关PCP进展快、死亡率高。磺胺类药物是PCP的一线治疗药物,诸多学者提倡自身免疫性疾病患者长期使用复方磺胺甲噁唑(trimethoprim-sulfamethoxazole,TMP-SMZ)预防PCP,但该药物不良反应及耐药性问题不容忽视。本文就自身免疫性疾病患者发生PCP的危险因素、使用TMP-SMZ预防PCP的有效性以及药物不良反应、耐受性、耐药性进行综述。
    作者贡献:阙咏图负责文献整理、论文撰写;李鹏冲负责论文修订;张奉春提出研究思路。
    利益冲突:所有作者均声明不存在利益冲突
  • [1] Eddens T, Kolls JK. Pathological and protective immunity to Pneumocystis infection[J]. Semin Immunopathol, 2015, 37: 153-162. doi:  10.1007/s00281-014-0459-z
    [2] Falagas ME, Manta KG, Betsi GI, et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review[J]. Clin Rheumatol, 2007, 26: 663-670. doi:  10.1007/s10067-006-0441-9
    [3] Catherinot E, Lanternier F, Bougnoux ME, et al. Pneumocystis jirovecii Pneumonia[J]. Infect Dis Clin North Am, 2010, 24: 107-138. doi:  10.1016/j.idc.2009.10.010
    [4] Godeau B, Coutant-Perronne V, Le Thi Huong D, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases[J]. J Rheumatol, 1994, 21: 246-251.
    [5] Chen M, Tian X, Qin F, et al. Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death[J]. PLoS One, 2015, 10: e0139144. doi:  10.1371/journal.pone.0139144
    [6] Park JW, Curtis JR, Moon J, et al. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids[J]. Ann Rheum Dis, 2018, 77: 644-649. doi:  10.1136/annrheumdis-2017-211796
    [7] Schmidt JJ, Lueck C, Ziesing S, et al. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years[J]. Crit Care, 2018, 22: 307. doi:  10.1186/s13054-018-2221-8
    [8] Fillatre P, Decaux O, Jouneau S, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients[J]. Am J Med, 2014, 127: 1242. e11-e17.
    [9] Ishikawa Y, Nakano K, Tokutsu K, et al. Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases[J]. RMD Open, 2021, 7: e001508. doi:  10.1136/rmdopen-2020-001508
    [10] Chew LC, Maceda-Galang LM, Tan YK, et al. Pneum-ocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid[J]. J Clin Rheumatol, 2015, 21: 72-75. doi:  10.1097/RHU.0000000000000215
    [11] Tasaka S, Tokuda H. Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies[J]. Kansenshogaku Zasshi, 2014, 88: 26-39.
    [12] Mekinian A, Durand-Joly I, Hatron PY, et al. Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome[J]. Rheumatology (Oxford), 2011, 50: 569-577. doi:  10.1093/rheumatology/keq314
    [13] Moosig F, Holle JU, Gross WL. Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?[J]. Arthritis Res Ther, 2009, 11: 253. doi:  10.1186/ar2826
    [14] Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality[J]. Arthritis Rheum, 1999, 42: 780-789. doi:  10.1002/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M
    [15] Matraiah EH, Olisaka N, Philipos M, et al. Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis[J]. Clin Rheumatol, 2018, 37: 1991-1996. doi:  10.1007/s10067-018-4155-6
    [16] Ghembaza A, Vautier M, Cacoub P, et al. Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases[J]. Chest, 2020, 158: 2323-2332. doi:  10.1016/j.chest.2020.05.558
    [17] Lertnawapan R, Totemchokchyakarn K, Nantiruj K, et al. Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus[J]. Rheumatol Int, 2009, 29: 491-496. doi:  10.1007/s00296-008-0721-6
    [18] Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis[J]. Arthritis Rheum, 1997, 40: 2187-2198. doi:  10.1002/art.1780401213
    [19] Blaas S. Pneumocystis jirovecii pneumonia in patients with autoimmune diseases[J]. Z Rheumatol, 2017, 76: 761-766. doi:  10.1007/s00393-017-0390-5
    [20] Gupta D, Zachariah A, Roppelt H, et al. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature[J]. J Clin Rheumatol, 2008, 14: 267-272. doi:  10.1097/RHU.0b013e31817a7e30
    [21] Redondo-Benito A, Curran A, Villar-Gomez A, et al. Opportunistic infections in patients with idiopathic inflammatory myopathies[J]. Int J Rheum Dis, 2018, 21: 487-496. doi:  10.1111/1756-185X.13255
    [22] Viguier M Fouéré S, De La Salmonière P, et al. Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy[J]. Medicine (Baltimore), 2003, 82: 82-86. doi:  10.1097/00005792-200303000-00002
    [23] Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases[J]. Dig Dis Sci, 2007, 52: 1481-1484. doi:  10.1007/s10620-006-9250-x
    [24] Tanaka M, Sakai R, Koike R, et al. Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors[J]. Mod Rheumatol, 2012, 22: 849-858. doi:  10.3109/s10165-012-0615-z
    [25] Rutherford AI, Patarata E, Subesinghe S, et al. Opportu-nistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis[J]. Rheumatology (Oxford), 2018, 57: 997-1001. doi:  10.1093/rheumatology/key023
    [26] Raychaudhuri SP, Siu S. Pneumocystis carinii pneumonia in patients receiving immunosuppressive drugs for dermatolog-ical diseases[J]. Br J Dermatol, 1999, 141: 528-530. doi:  10.1046/j.1365-2133.1999.03052.x
    [27] Wolfe RM, Peacock JE. Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?[J]. Curr Rheumatol Rep, 2017, 19: 35. doi:  10.1007/s11926-017-0664-6
    [28] Shams I, Ivory C, Cowan J. Duration of prednisone treatment before development of Pneumocystis jirovecii pneumonia in patients with vasculitis: A case series[J]. J Assoc Med Microbiol Infect Dis Can, 2022, 7: 117-124.
    [29] Park JW, Curtis JR, Kim MJ, et al. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole[J]. Arthritis Res Ther, 2019, 21: 207. doi:  10.1186/s13075-019-1996-6
    [30] Yeo KJ, Chen HH, Chen YM, et al. Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study[J]. BMC Infect Dis, 2020, 20: 112. doi:  10.1186/s12879-020-4826-1
    [31] Besada E, Nossent JC. Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?[J]. Clin Rheumatol, 2013, 32: 1677-1681. doi:  10.1007/s10067-013-2293-4
    [32] Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients[J]. Arthritis Rheum, 2009, 61: 305-312. doi:  10.1002/art.24283
    [33] Inokuma S. Search of official nationwide database in Japan for adverse events associated with disease-modifying antirheumatic drug therapies: focus on therapies in combination with methotrexate[J]. Expert Opin Drug Saf, 2021, 21: 573-580.
    [34] Ohmura SI, Homma Y, Masui T, et al. Factors Associated with Pneumocystis jirovecii Pneumonia in Patients with Rheumatoid Arthritis Receiving Methotrexate: A Single-center Retrospective Study[J]. Intern Med, 2021, 61: 997-1006.
    [35] 唐晓艳, 李冀, 董芬, 等. 儿童系统性红斑狼疮并发卡氏肺孢子虫肺炎临床分析[J]. 中华儿科杂志, 2013, 51: 920-924. doi:  10.3760/cma.j.issn.0578-1310.2013.12.008
    [36] Kageyama T, Furuta S, Ikeda K, et al. Prognostic factors of Pneumocystis pneumonia in patients with systemic autoimmune diseases[J]. PLoS One, 2019, 14: e0214324. doi:  10.1371/journal.pone.0214324
    [37] Avino LJ, Naylor SM, Roecker AM. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population[J]. Ann Pharmacother, 2016, 50: 673-679. doi:  10.1177/1060028016650107
    [38] Messiaen PE, Cuyx S, Dejagere T, et al. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review[J]. Transpl Infect Dis, 2017. doi:  10.1111/tid.12651.
    [39] 刘颜岗, 赵菲璠, 周庆涛, 等. 人类免疫缺陷病毒阴性重症肺孢子菌肺炎患者的临床特征分析[J]. 国际呼吸杂志, 2021, 41: 1126-1131. doi:  10.3760/cma.j.cn131368-20201224-01172
    [40] Nickel P, Schürmann M, Albrecht H, et al. Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients[J]. Infection, 2014, 42: 981-989. doi:  10.1007/s15010-014-0660-y
    [41] Ramos A. Infections in the immunocompromised host. What is the role of the medications?[J]. Reumatol Clin, 2008, 4: 1-6.
    [42] Wolfe RM, Beekmann SE, Polgreen PM, et al. Practice Patterns of Pneumocystis Pneumonia Prophylaxis in Connective Tissue Diseases: A Survey of Infectious Disease Physicians[J]. Open Forum Infect Dis, 2019, 6: ofz315. doi:  10.1093/ofid/ofz315
    [43] Utsunomiya M, Dobashi H, Odani T, et al. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial[J]. Arthritis Res Ther, 2017, 19: 7. doi:  10.1186/s13075-016-1206-8
    [44] Vananuvat P, Suwannalai P, Sungkanuparph S, et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases[J]. Semin Arthritis Rheum, 2011, 41: 497-502. doi:  10.1016/j.semarthrit.2011.05.004
    [45] Kimura M, Tanaka S, Ishikawa A, et al. Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease[J]. Rheumatol Int, 2008, 28: 673-676. doi:  10.1007/s00296-007-0505-4
    [46] Harada T, Kato R, Sueda Y, et al. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophy-laxis of Pneumocystis pneumonia in patients with rheumatic diseases[J]. Mod Rheumatol, 2021, 31: 629-635. doi:  10.1080/14397595.2020.1812834
    [47] Classen AY, Henze L, Von Lilienfeld-Toal M, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)[J]. Ann Hematol, 2021, 100: 1603-1620. doi:  10.1007/s00277-021-04452-9
    [48] Kawato R, Rokutanda R, Okada M, et al. Effect of Prophylactic Dose of Trimethoprim-Sulfamethoxazole on Serum Creatinine in Japanese Patients With Connective Tissue Diseases[J]. Clin Med Insights Arthritis Musculoskelet Disord, 2022, 15: 11795441221085141.
    [49] Otani T, Yamaguchi K, Sakamoto S, et al. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study[J]. Pulm Pharmacol Ther, 2021, 67: 101999. doi:  10.1016/j.pupt.2021.101999
    [50] Maezawa R, Kurasawa K, Arai S, et al. Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases[J]. Mod Rheumatol, 2013, 23: 62-70. doi:  10.3109/s10165-012-0625-x
    [51] Pereda CA, Nishishinya-Aquino MB, Brito-García N, et al. Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?[J]. Rheumatol Int, 2021, 41: 1419-1427. doi:  10.1007/s00296-021-04808-4
    [52] Jinno S, Akashi K, Onishi A, et al. Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids[J]. Rheumatol Int, 2021, 42: 1403-1409.
    [53] 王梦嫣, 朱彪. 耶氏肺孢子菌对磺胺类药物耐药相关基因突变的研究进展[J]. 浙江大学学报(医学版), 2017, 46: 563-569. doi:  10.3785/j.issn.1008-9292.2017.10.18
    [54] Ponce CA, Chabé M, George C, et al. High Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Gene Mutations in Patients with a First Episode of Pneumocystis Pneumonia in Santiago, Chile, and Clinical Response to Trimethoprim-Sulfamethoxazole Therapy[J]. Antimicrob Agents Chemother, 2017, 61: e01290-e01316.
    [55] Montesinos I, Delforge ML, Ajjaham F, et al. Evaluation of a new commercial real-time PCR assay for diagnosis of Pneumocystis jirovecii pneumonia and identification of dihydropteroate synthase (DHPS) mutations[J]. Diagn Microbiol Infect Dis, 2017, 87: 32-36.
    [56] Hauser PM, Nahimana A, Taffe P, et al. Interhuman transmission as a potential key parameter for geographical variation in the prevalence of Pneumocystis jirovecii dihydropteroate synthase mutations[J]. Clin Infect Dis, 2010, 51: e28-e33.
    [57] Esteves F, Gaspar J, Marques T, et al. Identification of relevant single-nucleotide polymorphisms in Pneumocystis jirovecii: relationship with clinical data[J]. Clin Microbiol Infect, 2010, 16: 878-884.
  • 加载中
计量
  • 文章访问数:  202
  • HTML全文浏览量:  47
  • PDF下载量:  83
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-03-20
  • 录用日期:  2022-04-25
  • 刊出日期:  2023-01-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!